Discovery/R&D

  1. Academia + Industry with BridgeBio's Dr. Michael Henderson 6/21/2021

    BridgeBio has a whopping 30+ pre-clinical to clinical-stage candidates in its pipeline representing an impressive array of modalities and targets. It boasts a couple of commercial wins under its belt. The company is no stranger to developing business strategies for success. Central to that success are partnerships with scientists and researchers to fuel pipeline expansion. On this episode of The Business of Biotech, BridgeBio Chief Business Officer Michael Henderson, M.D. walks us through the formula behind the company's academia-led growth strategy.

  2. AI & The Human Genome 2/22/2021

    From his Fellowship at the NIH Human Genome Research Institute to his leadership as CEO at NeuBase Therapeutics, Dr. Dietrich Stephan is recognized as a pioneer in the field of genomic precision medicine. On this episode of The Business of Biotech, Dr. Stephan shares how artificial intelligence is shaping the acceleration of genomic medicine discovery at NeuBase and beyond, with plenty of practical insight on how to adopt and leverage the technology.

  3. Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, Ph.D. 4/10/2024

    Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.

  4. Executing A Product Pivot With Vir's Mark Eisner, MD 5/7/2025

    On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research.

  5. Bacterial Therapy: Modulation Of The Microbiome 11/24/2020

    Dr. Bernat Olle, CEO joins The Business of Biotech to talk about the pioneering work that his company, Vedanta Biosciences, is doing to modulate the immune system and provide colonization resistance against infectious pathogens -- particularly those contracted during hospital stays. Learn about Dr. Olle's leadership of a company that's pioneering the exploration of immune-regulating and immune-potentiating bacteria that live in association with humans.

  6. RNA-Engineered Cell Therapy With Cartesian's Dr. Murat Kalayoglu 6/10/2021

    Cartesian President & CEO Murat Kalayoglu, M.D., Ph.D. has led three of his company's six autoimmune, oncology, and respiratory candidates through Phase I/II clinical trials and two more of them are on the cusp of entering Phase I this year. With so many programs in and entering the clinic, he's a great choice for a conversation on GMP expectations for phase I first-in-human trials. Glean insight from Cartesian's experiences and learn about the company's novel approach to RNA-engineered cell therapies for oncology and beyond on this episode of The Business of Biotech.

  7. A Vaccine For Type 1 Diabetes With Diamyd Medical's Dr. Ulf Hannelius 7/19/2021

    As leaders at Diamyd Medical made plans to manufacture clinical supply of therapies aimed at preserving and restoring insulin production in Type 1 diabetes patients, outsourced production was on the table. Then, the company doubled down on its intentions and built out its own manufacturing facility. On this week's episode of The Business of Biotech, Diamyd Medical President & CEO Dr. Ulf Hannelius tells us all about the therapies his company is developing, plus the why and the how behind the company's choice to manufacture them in-house.

  8. The Generalist Biotech CEO With Seekyo's Oury Chetboun 7/30/2025

    On this week's Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment.

  9. ML-Enabled Drug Discovery With LabGenius' James Field, Ph.D. 7/6/2023

    We explore the intersection of tech and bio with Dr. James Field, founder and CEO of LabGenius. If you're concerned with what ML will do to — or for — your biopharma business, don't miss this episode

  10. Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D. 12/12/2022

    While many gene therapy development efforts focus on rare disease, Xalud Therapeutics is taking a swing that, measured in addressable patient market terms, is considerably bigger. Osteoarthritis, or OA, is a chronic, progressive joint disease that affects over 30 million people in the United States. On this episode of the Business of Biotech, we catch up with Xalud Chief Medical Officer Howard Rutman, M.D., MBA for a discussion on the company's late-stage plasmid DNA gene therapy that's showing promise in OA and other chronic inflammatory conditions.